Advaxis Inc
F:FAD2
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Advaxis Inc
F:FAD2
|
12.4m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Advaxis Inc
Glance View
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.
